Gene: LLGL2

3993
HGL|Hugl-2|LGL2
LLGL2, scribble cell polarity complex component
protein-coding
17q25.1
Ensembl:ENSG00000073350 Vega:OTTHUMG00000179685 UniprotKB:Q6P1M3
NC_000017.11
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
6.887e-1 (AD)  7.113e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg13620705chr17:73559492LLGL28.880e-16Alcohol consumption per day27843151

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TMC60.87
NDE10.835
LDLRAP10.834
CLMN0.823
SYNGR20.819
TFEB0.819
CDC42EP10.81
PPFIBP20.801
TJAP10.8
MYO1E0.792

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
FAM163A-0.363
GALNTL6-0.351
CRH-0.346
NPBWR1-0.341
KMO-0.337
FREM3-0.336
VIP-0.334
TPBGL-0.33
CUX2-0.329
EPHA6-0.329

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in decreased expression of LLGL2 mRNA"28903501
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LLGL2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LLGL2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LLGL2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LLGL2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LLGL2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LLGL2 mRNA"27188386
D018501Antirheumatic AgentsAntirheumatic Agents affects the expression of LLGL2 mRNA24449571
C006632arsenic trioxideLLGL2 protein results in decreased susceptibility to arsenic trioxide20707922
D004958EstradiolESR1 protein affects the reaction [Estradiol promotes the reaction [NCOA1 protein binds to LLGL2 gene]]17962382
D004958EstradiolESR1 protein affects the reaction [Estradiol promotes the reaction [NCOA2 protein binds to LLGL2 gene]]17962382
D004958EstradiolEstradiol promotes the reaction [ESR1 protein binds to LLGL2 gene]17962382
D004958EstradiolEstradiol results in decreased expression of LLGL2 mRNA21185374
C006780bisphenol Abisphenol A affects the expression of LLGL2 mRNA21786754
C006780bisphenol Abisphenol A results in decreased expression of LLGL2 mRNA25181051
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of LLGL2 mRNA17484886
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of LLGL2 gene20938992
D003300CopperCopper results in decreased expression of LLGL2 mRNA26293553
D016572CyclosporineCyclosporine results in decreased expression of LLGL2 mRNA20106945
D016572CyclosporineCyclosporine results in increased expression of LLGL2 mRNA25562108
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of LLGL2 mRNA]27941970
D002945CisplatinCisplatin results in decreased expression of LLGL2 mRNA27392435
D004121Dimethyl SulfoxideDimethyl Sulfoxide affects the expression of LLGL2 mRNA24834073
D004147DioxinsDioxins affects the expression of LLGL2 mRNA20463971
C024565ethylene dichlorideethylene dichloride results in increased expression of LLGL2 mRNA28189721
C082360fipronilfipronil results in decreased expression of LLGL2 mRNA23962444
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of LLGL2 gene20938992
C069837fullerene C60fullerene C60 results in increased expression of LLGL2 mRNA19167457
C039281furanfuran results in increased methylation of LLGL2 gene22079235
D006534Heptachlor EpoxideHeptachlor Epoxide results in increased expression of LLGL2 mRNA25270620
D017313FenretinideFenretinide results in increased expression of LLGL2 mRNA28973697
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of LLGL2 gene20938992
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in increased expression of LLGL2 mRNA24810058
C016599mono-(2-ethylhexyl)phthalatemono-(2-ethylhexyl)phthalate results in increased expression of LLGL2 mRNA22401849
C568376MT19c compoundMT19c compound results in decreased expression of LLGL2 mRNA21781307
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of LLGL2 mRNA"25554681
D009532NickelNickel results in decreased expression of LLGL2 mRNA12540486
C029938nickel sulfatenickel sulfate results in increased expression of LLGL2 mRNA22714537
C018620oleoresinsoleoresins results in increased expression of LLGL2 mRNA20008804
D010416PentachlorophenolPentachlorophenol results in increased expression of LLGL2 mRNA23892564
C006253pirinixic acidpirinixic acid results in increased expression of LLGL2 mRNA18301758
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of LLGL2 mRNA25895662
D012906SmokeSmoke results in decreased expression of LLGL2 mRNA21095227
D012969Sodium FluorideSodium Fluoride results in increased expression of LLGL2 protein28918527
D013629TamoxifenTamoxifen results in decreased expression of LLGL2 mRNA25123088
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of LLGL2 mRNA26290441
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of LLGL2 mRNA21215274
D014212TretinoinTretinoin results in increased expression of LLGL2 mRNA20488242
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LLGL2 mRNA"27188386
C012589trichostatin Atrichostatin A affects the expression of LLGL2 mRNA28542535
C012589trichostatin Atrichostatin A results in decreased expression of LLGL2 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LLGL2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of LLGL2 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of LLGL2 mRNA26272509
D014635Valproic AcidValproic Acid results in increased methylation of LLGL2 gene29154799
D014635Valproic AcidValproic Acid results in increased expression of LLGL2 mRNA20546886
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of LLGL2 gene25560391
C025643vinclozolinvinclozolin results in decreased expression of LLGL2 mRNA23034163
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LLGL2 mRNA"27188386
C088658zoledronic acidzoledronic acid results in increased expression of LLGL2 mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005096GTPase activator activity-IBA21873635  
GO:0005515protein binding-IPI12725730  15632202  
GO:0017137Rab GTPase binding-IBA21873635  
GO:0019905syntaxin binding-IBA21873635  
GO:0030165PDZ domain binding-IPI12725730  
GO ID GO Term Qualifier Evidence PubMed
GO:0006887exocytosis-IEA-  
GO:0007049cell cycle-IEA-  
GO:0008593regulation of Notch signaling pathway-IBA21873635  
GO:0017157regulation of exocytosis-IBA21873635  
GO:0030866cortical actin cytoskeleton organization-IBA21873635  
GO:0032878regulation of establishment or maintenance of cell polarity-IBA21873635  
GO:0032878regulation of establishment or maintenance of cell polarity-IDA12725730  
GO:0043547positive regulation of GTPase activity-IEA-  
GO:0050708regulation of protein secretion-IBA21873635  
GO:0051294establishment of spindle orientation-IBA21873635  
GO:0051301cell division-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005737cytoplasm-IBA21873635  
GO:0005737cytoplasm-IDA15632202  
GO:0005829cytosol-IDA-  
GO:0005886plasma membrane-IBA21873635  
GO:0030864cortical actin cytoskeleton-IBA21873635  
GO:0043231intracellular membrane-bounded organelle-IDA-  
KEGG ID KEGG Term
hsa04530Tight junction
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25813534Association of genetic variants with hypertension in a longitudinal population-based genetic epidemiological study. (2015 May)Yamada YInt J Mol Med